Newly identified oncolytic VSV-GP-specific CD8+ T cell epitopes for monitoring of anti-viral immune responses in the BALB/c mouse model [0.03%]
在BALB/c小鼠模型中识别新的VSV-GP特异性CD8⁺T细胞表位以监测抗病毒免疫反应
Sarah Danklmaier,Saskia V Vijver,Lisa Pipperger et al.
Sarah Danklmaier et al.
The vesicular stomatitis virus variant VSV-GP is an oncolytic virus (OV) platform extensively studied in preclinical settings, which recently entered clinical trial testing. For oncolytic virotherapy, innate and adaptive immune system activ...
ZEB1, a novel junctional adhesion molecule A regulator, impacts sensitivity of pancreatic cancer-associated fibroblasts to reovirus [0.03%]
ZEB1通过调控胰腺癌相关成纤维细胞对呼肠孤病毒的敏感性影响肿瘤进展
Nicole Dam,Tom J Harryvan,Hao Dang et al.
Nicole Dam et al.
Oncolytic virus (OV) therapy is a promising treatment for various tumors. However, in pancreatic ductal adenocarcinoma (PDAC), the high abundance of cancer-associated fibroblasts (CAFs) can limit OV therapy efficacy by impairing viral sprea...
Longitudinal tracking of MALAT1 level over a breast cancer patient's course of treatment and disease progression [0.03%]
乳腺癌患者治疗过程中MALAT1水平的纵向跟踪及疾病进展监测研究
Disha Aggarwal,Tse-Luen Wee,Shuchismita Satpathy et al.
Disha Aggarwal et al.
Long non-coding RNAs (lncRNAs) have emerged as important regulators of the hallmarks of cancer, yet their potential remains under-explored in clinical studies. Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1), an lncRNA upreg...
Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma [0.03%]
编码中性粒细胞活化蛋白的溶瘤麻疹病毒治疗对滑膜肉瘤有效
Steven I Robinson,Susan M Clark,Ianko D Iankov et al.
Steven I Robinson et al.
Synovial sarcoma (SS) is an aggressive mesenchymal malignancy that is refractory to treatment with immune checkpoint inhibitor-based therapy. We investigated the infiltrating T cell immune status in archived patient samples and tested the e...
Mariana Esteves,Ana Miguel Matos,Maria Teresa Cruz
Mariana Esteves
Pancreatic cancer, particularly the exocrine-type pancreatic ductal adenocarcinoma, has a dismal prognosis, with a 5-year survival rate of only 2%-9%, depending on the geographic region. The high aggressiveness of this malignancy is attribu...
Nanobody-based canine PD-L1-targeting immune checkpoint inhibitors for cancer therapy in dogs [0.03%]
基于纳米抗体的犬PD-L1靶向免疫检查点抑制剂用于犬癌症治疗
Morgane Di Palma Subran,Marianne Wyss,Betül Taskoparan et al.
Morgane Di Palma Subran et al.
Although the demand for novel immunotherapies to treat companion dogs with spontaneously developing cancer is increasing in high-income countries, most options remain inaccessible. Dogs host a complete and functional immune system reacting ...
Targeting oncogenic fusion-driven NUT carcinoma with CRISPR-Cas9 genome editing [0.03%]
利用CRISPR-Cas9基因组编辑靶向致癌融合驱动的NUT癌
Maxim F Carle,Tahereh Mohammadian Gol,Justin S Antony et al.
Maxim F Carle et al.
NUT carcinoma (NC) is a highly aggressive malignancy characterized by an oncogenic fusion gene incorporating the NUTM1 gene. To date, no established treatment options exist. CRISPR-Cas9 technology allows precise genomic targeting, thereby p...
GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts [0.03%]
GPC2-CART细胞对髓母细胞瘤异种移植瘤具有强大的体内抗肿瘤活性
Reona Okada,Mia Fanuzzi,Constanza Rodriguez et al.
Reona Okada et al.
Medulloblastoma (MB) is the most common malignant brain tumor in children. Patients with group 3 and 4 MB have poor clinical outcomes, underscoring the urgent need for new therapies. Glypican-2 (GPC2) is a recently discovered oncofetal anti...
Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells [0.03%]
通过碱基编辑在原代T细胞中安装FAS和TGFβR2显性负突变体
Bryce J Wick,Mitchell G Kluesner,Nicholas J Slipek et al.
Bryce J Wick et al.
Adoptive cell transfer (ACT) of engineered T cells is effective against B cell malignancies but has faltered against solid tumors due to the immunosuppressive tumor microenvironment (TME). FAS ligand (FASL) and transforming growth factor β...
Myeloid-derived suppressor cells inhibit the replication of oncolytic virus by reducing intratumoral arginine levels [0.03%]
髓源性抑制细胞通过降低瘤内精氨酸水平来抑制溶瘤病毒的复制
Parker Dryja,Erica B Flores,Mee Y Bartee et al.
Parker Dryja et al.
Oncolytic virotherapy uses replication-competent viruses to treat various solid tumors. While much of the clinical efficacy of oncolytic virotherapy is mediated by anti-tumor T cell responses, most of these therapies still rely on the in vi...